The systemic use of procaine in the treatment of the elderly: a review

J Am Geriatr Soc. 1977 Jan;25(1):1-19. doi: 10.1111/j.1532-5415.1977.tb00917.x.

Abstract

This article is a review and evaluation of the world literature on the systemic use of procaine in the treatment of the aging process and the common chronic diseases of later life. Included are data from 285 articles and books, describing treatment in more than 100,000 patients in the past 25 years. Except for a possible antidepressant effect, there is no convincing evidence that procaine (or Gerovital, of which procaine is the major component) has any value in the treatment of disease in older patients. If procaine has an antidepressant effect, there is some likelihood that this accounts for the reports of decreased complaints referable to the musculoskeletal, cardiovascular, endocrine sexual, gastrointestinal and respiratory systems.

MeSH terms

  • 4-Aminobenzoic Acid / pharmacology
  • Adult
  • Affect / drug effects
  • Aged
  • Aging / drug effects*
  • Arteriosclerosis / drug therapy
  • Arthritis / drug therapy
  • Chronic Disease
  • Dementia / drug therapy
  • Depression / drug therapy
  • Endocrine Glands / drug effects
  • Female
  • Hair / drug effects
  • Humans
  • Hydrogen-Ion Concentration
  • Hypertension / drug therapy
  • Intracranial Arteriosclerosis / drug therapy
  • Male
  • Middle Aged
  • Monoamine Oxidase Inhibitors
  • Nervous System / drug effects
  • Procaine / administration & dosage*
  • Procaine / pharmacology
  • Procaine / therapeutic use
  • Sexual Dysfunction, Physiological / drug therapy
  • Skin / drug effects

Substances

  • Monoamine Oxidase Inhibitors
  • Procaine
  • 4-Aminobenzoic Acid